Reactive arthritis
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Prognosis
Approximately 50% of patients can expect symptoms to resolve within the first 6 months.[46]Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy with special reference to chlamydia-induced arthritis. A prospective, randomized 9-month comparison. J Rheumatol. 2004;31:1973-1980. http://www.ncbi.nlm.nih.gov/pubmed/15468362?tool=bestpractice.com [82]Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002;136:896-907. http://www.ncbi.nlm.nih.gov/pubmed/12069564?tool=bestpractice.com However, 30% to 50% of patients will develop chronic ReA.[46]Carter JD, Valeriano J, Vasey FB. Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy with special reference to chlamydia-induced arthritis. A prospective, randomized 9-month comparison. J Rheumatol. 2004;31:1973-1980. http://www.ncbi.nlm.nih.gov/pubmed/15468362?tool=bestpractice.com [82]Khan MA. Update on spondyloarthropathies. Ann Intern Med. 2002;136:896-907. http://www.ncbi.nlm.nih.gov/pubmed/12069564?tool=bestpractice.com [83]Colmegna I, Espinoza LR. Recent advances in reactive arthritis. Curr Rheumatol Rep. 2005;7:201-207. http://www.ncbi.nlm.nih.gov/pubmed/15918996?tool=bestpractice.com [84]Leirisalo-Repo M, Helenius P, Hannu T, et al. Long-term prognosis of reactive salmonella arthritis. Ann Rheum Dis. 1997;56:516-520. http://www.ncbi.nlm.nih.gov/pubmed/9370874?tool=bestpractice.com [85]Yli-Kerttula T, Tertti R, Toivanen A. Ten-year follow up study of patients from a Yersinia pseudotuberculosis III outbreak. Clin Exp Rheumatol. 1995;13:333-337. http://www.ncbi.nlm.nih.gov/pubmed/7554560?tool=bestpractice.com [86]Rihl M, Klos A, Kohler L, et al. Infection and musculoskeletal conditions: reactive arthritis. Best Pract Res Clin Rheumatol. 2006;20:1119-1137. http://www.ncbi.nlm.nih.gov/pubmed/17127200?tool=bestpractice.com
Use of this content is subject to our disclaimer